• 

  BHU study: Over 30 per cent of Covaxin recipients report adverse events

  India | May 16, 2024 23:41 IST

  The one-year follow-up study, involving 926 participants, highlighted the long-term safety of the BBV152 vaccine, with serious adverse events like stroke and Guillain-Barre syndrome reported in one percent of recipients.

• 

  COVID-19: 3 lakh doses of intranasal vaccine 'iNCOVACC' sent to hospitals, informs Bharat Biotech

  India | February 05, 2023 18:29 IST

  COVID-19 vaccine: iNCOVACC, the world's first intranasal COVID-19 vaccine, was launched on January 26 (Thursday). The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments.

• 

  What is nasal vaccine - iNCOVACC? All you need to know

  Health | January 27, 2023 13:15 IST

  Covid19 nasal vaccine: The nasal vaccine was launched on the occasion of the 74th Independence Day to the public in the national capital by Union Health Minister Mansukh Mandaviya.

• 

  First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26

  India | January 21, 2023 20:11 IST

  Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month to sell the nasal vaccine in India. The vaccine is also available on the CoWIN platform.

• 

  Bharat Biotech's nasal vaccine for Covid to cost Rs 800 for private hospitals, Rs 325 for govts

  India | December 27, 2022 13:11 IST

  The nasal vaccine, iNCOVACC, which will be rolled out in the fourth week of January is for those above 18 years of age. The slots for the vaccine can now be booked on CoWin's portal.

• 

  Centre rejects media reports claiming approval for Covaxin rushed due to political pressure

  India | November 17, 2022 14:46 IST

  The government said the scientific approach and prescribed norms adhered to in approving Covid-19 vaccines for Emergency Use Authorization.

• 

  COVID: 50 million Covaxin doses set to expire due to poor off take

  India | November 06, 2022 13:41 IST

  Covaxin news: “Covaxin doses in vials are set to expire during early 2023, resulting in losses for the company,” said sources.

• 

  Covid-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval

  India | September 06, 2022 15:37 IST

  This will be India's first nasal vaccine for COVID-19. Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19.

• 

  Japan has approved Covaxin booster dose for travellers: Bharat Biotech

  India | August 05, 2022 22:56 IST

  In April this year, the Japanese government announced including Covaxin in its list of recognized vaccines to further facilitate travel from India.

• 

  Bharat Biotech's COVID-19 nasal vaccine phase III trials completed

  India | June 19, 2022 6:54 IST

  Krishna was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year.

• 

  Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech

  India | June 17, 2022 12:25 IST

  A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer-reviewed high impact factor journal.

Advertisement
• 

  Germany recognises Bharat Biotech's Covaxin for travel from June 1

  India | May 26, 2022 12:07 IST

  The DCGI in April also granted an emergency use authorisation (EUA) to Covaxin for the age group of 6-12 years.

• 

  COVID vaccination: DCGI asks Bharat Biotech to provide more data on Covaxin for below 12-year-olds

  India | April 22, 2022 14:09 IST

  This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years.

• 

  Bharat Biotech to soon rectify issues raised by WHO on Covaxin, say sources

  India | April 05, 2022 6:58 IST

  Recently, in a statement on WHO's suspension of Covaxin, Bharat Biotech said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."

• 

  Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies

  India | April 04, 2022 10:10 IST

  Earlier on Sunday, Bharat Biotech had said it had nothing else to add to an earlier statement where it said it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.

• 

  No impact on efficacy and safety of Covaxin: Bharat Biotech after WHO suspension

  India | April 03, 2022 9:48 IST

  The vaccine manufacturer has further said that the company is slowing down the production of Covaxin for facility optimization.

• 

  Bharat Biotech says slowing down Covaxin production for facility optimisation

  India | April 01, 2022 23:20 IST

  The company said after the recent WHO post Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements.

• 

  Bharat Biotech gets approval for intranasal Covid-19 booster dose trials

  India | January 28, 2022 15:56 IST

  An intranasal vaccine as a booster dose if becomes a reality would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.

• 

  Covaxin now universal vaccine for adults, children: Bharat Biotech

  India | January 14, 2022 7:26 IST

  Earlier, Hyderabad-based Hyderabad-based vaccine manufacturer had claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.

• 

  Covaxin booster dose neutralises Omicron, as well as Delta variants, says Bharat Biotech

  India | January 12, 2022 18:26 IST

  Covaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.